



PATENT
Docket No.: 19603/4071 (CRF D-2598A)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Vivian E. Mack Strong et al.)	Examiner:
Serial No.	:	09/782,936)	Frederick F. Krass
Cnfrm. No.	:	1665)	Art Unit:
Filed	:	February 14, 2001)	1614
For	:	USE OF COX-2 INHIBITORS TO TREAT SEPSIS, COMPLICATIONS THEREOF, AND EP RECEPTOR MODULATION)	

RESPONSE TO COMMUNICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the February 2, 2004, communication from the U.S. Patent and Trademark Office ("PTO"), applicants hereby elect the method of treating patients at risk for systemic inflammatory response syndrome. In addition, applicants confirm the election of sepsis as the sub-modality. These elections are made with traverse. It is submitted that all of the identified groups of invention and species are closely related and, therefore, can be searched and examined together without undue burden on the PTO. Accordingly, it is submitted that the restriction requirement/election of species requirement should be withdrawn.

Respectfully submitted,

Date: March 12, 2004



Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603
Telephone: (585) 263-1304
Facsimile: (585) 263-1600


R754604.1

Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

3/12/04

Date



Wendy L. Barry